Xceleron is a world leader in the use of Accelerator Mass Spectrometry (AMS) analytical technology in pharmaceutical, food technology and crop protection applications.
Our primary business is in pharmaceutical research and development. Since 1998 we have been helping to design preclinical and clinical investigations around the unique analytical features of AMS, now a widely used and valuable tool in the quest for improved R&D efficiency. Smart use of AMS allows analytical challenges to be taken off the critical path by supporting time- and cost-efficient investigations.
Xceleron can help you to design and implement preclinical and clinical fit-for-purpose investigations. Our clients regularly use us to meet commercial objectives associated with:
Dedicated to pharmaceutical R&D support
We’ve supported over 150 pharmaceutical companies
20—30 client studies per year
15—20 clients per year
50% of our business is from repeat clients
We process 20,000 to 30,000 samples annually
Over 95% of our AMS studies are conducted at a full therapeutic dose by intended therapeutic route
12 marketed drugs have used Xceleron AMS data
In 2013 the FDA approved 27 new drugs. 6 contained AMS data & 5 of those contained Xceleron data
AMS is a unique analytical platform because it does not suffer from matrix effects, can be applied across a broad range of compound types, including small molecule and biologics, and is exquisitely sensitive. Xceleron has developed proprietary approaches to analytical method validation and can apply AMS in a clinical setting that is very efficient.
We have supported over 100 pharmaceutical and biotechnology companies in target research, preclinical development and clinical Phases 0, I and II/III. Our use of the AMS analytical platform has enabled R&D teams to increase R&D efficiency and reach their commercial objectives.